- Home
- BRLT vs CMMB Comparison
BRLT vs CMMB Comparison
Compare BRLT & CMMB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- BRLT
- CMMB
- Stock Information
- Founded
- BRLT 2005
- CMMB 2004
- Country
- BRLT United States
- CMMB Israel
- Employees
- BRLT N/A
- CMMB N/A
- Industry
- BRLT Consumer Specialties
- CMMB Biotechnology: Pharmaceutical Preparations
- Sector
- BRLT Consumer Discretionary
- CMMB Health Care
- Exchange
- BRLT Nasdaq
- CMMB Nasdaq
- Market Cap
- BRLT 19.8M
- CMMB 22.0M
- IPO Year
- BRLT 2021
- CMMB N/A
- Fundamental
- Price
- BRLT $2.36
- CMMB $2.83
- Analyst Decision
- BRLT Hold
- CMMB Strong Buy
- Analyst Count
- BRLT 2
- CMMB 2
- Target Price
- BRLT $1.80
- CMMB $26.50
- AVG Volume (30 Days)
- BRLT 306.9K
- CMMB 141.5K
- Earning Date
- BRLT 11-06-2025
- CMMB 11-13-2025
- Dividend Yield
- BRLT 10.50%
- CMMB N/A
- EPS Growth
- BRLT N/A
- CMMB N/A
- EPS
- BRLT N/A
- CMMB N/A
- Revenue
- BRLT $422,218,000.00
- CMMB N/A
- Revenue This Year
- BRLT $5.55
- CMMB N/A
- Revenue Next Year
- BRLT $3.88
- CMMB N/A
- P/E Ratio
- BRLT N/A
- CMMB N/A
- Revenue Growth
- BRLT N/A
- CMMB N/A
- 52 Week Low
- BRLT $1.25
- CMMB $2.71
- 52 Week High
- BRLT $3.10
- CMMB $9.84
- Technical
- Relative Strength Index (RSI)
- BRLT 49.28
- CMMB 21.60
- Support Level
- BRLT $2.75
- CMMB $2.96
- Resistance Level
- BRLT $2.70
- CMMB $3.09
- Average True Range (ATR)
- BRLT 0.28
- CMMB 0.21
- MACD
- BRLT -0.07
- CMMB 0.00
- Stochastic Oscillator
- BRLT 26.00
- CMMB 11.26
About BRLT Brilliant Earth Group Inc.
Brilliant Earth Group Inc is a digitally native omnichannel jewelry company. The company designs, procures and sells ethically-sourced diamonds, gemstones and jewelry online and through showrooms. The sales of the company consist of revenue from diamond, gemstone, and jewelry retail sales. The company sells its products in the U.S. and other international countries, of which a majority of revenue is derived from the U.S.
About CMMB Chemomab Therapeutics Ltd.
Chemomab Therapeutics Ltd is a clinical-stage biotech company, focusing on the discovery and development of therapeutics for fibrosis-related diseases with large unmet needs. The company's candidate, CM-101, is a monoclonal antibody that targets CCL24 and was shown to interfere with the underlying biology of liver, skin, and lung fibrosis using a novel and differentiated mechanism of action. CM-101 has demonstrated the potential to treat multiple severe and life-threatening fibrotic and inflammatory diseases. It is advancing three Phase 2 clinical trials in parallel for CM-101, treating rare fibrotic conditions.